Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4.90
ALIOF's Cash to Debt is ranked lower than
64% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ALIOF: 4.90 )
Ranked among companies with meaningful Cash to Debt only.
ALIOF' s 10-Year Cash to Debt Range
Min: 2.7  Med: 4.20 Max: N/A
Current: 4.9
Equity to Asset 0.72
ALIOF's Equity to Asset is ranked higher than
54% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALIOF: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5  Med: 0.57 Max: 0.72
Current: 0.72
0.5
0.72
Interest Coverage 58.07
ALIOF's Interest Coverage is ranked lower than
84% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 58.07 )
Ranked among companies with meaningful Interest Coverage only.
ALIOF' s 10-Year Interest Coverage Range
Min: 0.3  Med: 58.07 Max: 9999.99
Current: 58.07
0.3
9999.99
F-Score: 7
Z-Score: 15.19
M-Score: -2.36
WACC vs ROIC
8.15%
63.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.29
ALIOF's Operating margin (%) is ranked higher than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. ALIOF: 30.29 )
Ranked among companies with meaningful Operating margin (%) only.
ALIOF' s 10-Year Operating margin (%) Range
Min: 0.68  Med: 23.70 Max: 29.11
Current: 30.29
0.68
29.11
Net-margin (%) 31.22
ALIOF's Net-margin (%) is ranked higher than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. ALIOF: 31.22 )
Ranked among companies with meaningful Net-margin (%) only.
ALIOF' s 10-Year Net-margin (%) Range
Min: -8.15  Med: 18.92 Max: 30.33
Current: 31.22
-8.15
30.33
ROE (%) 33.55
ALIOF's ROE (%) is ranked higher than
96% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. ALIOF: 33.55 )
Ranked among companies with meaningful ROE (%) only.
ALIOF' s 10-Year ROE (%) Range
Min: -8.85  Med: 27.86 Max: 53.58
Current: 33.55
-8.85
53.58
ROA (%) 23.73
ALIOF's ROA (%) is ranked higher than
97% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. ALIOF: 23.73 )
Ranked among companies with meaningful ROA (%) only.
ALIOF' s 10-Year ROA (%) Range
Min: -5.18  Med: 14.90 Max: 21.05
Current: 23.73
-5.18
21.05
ROC (Joel Greenblatt) (%) 118.03
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. ALIOF: 118.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALIOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5.55  Med: 89.44 Max: 161.39
Current: 118.03
-5.55
161.39
Revenue Growth (3Y)(%) 3.70
ALIOF's Revenue Growth (3Y)(%) is ranked higher than
55% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ALIOF: 3.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALIOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.8  Med: 2.10 Max: 21.5
Current: 3.7
-25.8
21.5
EBITDA Growth (3Y)(%) 131.30
ALIOF's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ALIOF: 131.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALIOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.4  Med: 4.35 Max: 131.3
Current: 131.3
-48.4
131.3
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.60
ALIOF's P/E(ttm) is ranked higher than
69% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 40.90 vs. ALIOF: 25.60 )
Ranked among companies with meaningful P/E(ttm) only.
ALIOF' s 10-Year P/E(ttm) Range
Min: 13.52  Med: 19.24 Max: 66.51
Current: 25.6
13.52
66.51
Forward P/E 23.53
ALIOF's Forward P/E is ranked higher than
52% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. ALIOF: 23.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.60
ALIOF's PE(NRI) is ranked higher than
68% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 39.90 vs. ALIOF: 25.60 )
Ranked among companies with meaningful PE(NRI) only.
ALIOF' s 10-Year PE(NRI) Range
Min: 13.54  Med: 19.23 Max: 66.51
Current: 25.6
13.54
66.51
P/B 7.97
ALIOF's P/B is ranked lower than
69% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. ALIOF: 7.97 )
Ranked among companies with meaningful P/B only.
ALIOF' s 10-Year P/B Range
Min: 2.35  Med: 3.83 Max: 8.13
Current: 7.97
2.35
8.13
P/S 7.99
ALIOF's P/S is ranked higher than
60% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. ALIOF: 7.99 )
Ranked among companies with meaningful P/S only.
ALIOF' s 10-Year P/S Range
Min: 1.96  Med: 3.65 Max: 16.68
Current: 7.99
1.96
16.68
PFCF 27.44
ALIOF's PFCF is ranked higher than
67% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 41.97 vs. ALIOF: 27.44 )
Ranked among companies with meaningful PFCF only.
ALIOF' s 10-Year PFCF Range
Min: 8.65  Med: 23.02 Max: 2760
Current: 27.44
8.65
2760
POCF 26.09
ALIOF's POCF is ranked higher than
62% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. ALIOF: 26.09 )
Ranked among companies with meaningful POCF only.
ALIOF' s 10-Year POCF Range
Min: 8.43  Med: 15.67 Max: 240
Current: 26.09
8.43
240
EV-to-EBIT 24.95
ALIOF's EV-to-EBIT is ranked higher than
57% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. ALIOF: 24.95 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIOF' s 10-Year EV-to-EBIT Range
Min: -53.3  Med: 14.50 Max: 261.7
Current: 24.95
-53.3
261.7
PEG 1.74
ALIOF's PEG is ranked higher than
70% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.75 vs. ALIOF: 1.74 )
Ranked among companies with meaningful PEG only.
ALIOF' s 10-Year PEG Range
Min: 0  Med: 0.00 Max: 0
Current: 1.74
Shiller P/E 48.44
ALIOF's Shiller P/E is ranked higher than
50% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.44 vs. ALIOF: 48.44 )
Ranked among companies with meaningful Shiller P/E only.
ALIOF' s 10-Year Shiller P/E Range
Min: 30.64  Med: 39.20 Max: 49.51
Current: 48.44
30.64
49.51
Current Ratio 2.74
ALIOF's Current Ratio is ranked lower than
66% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. ALIOF: 2.74 )
Ranked among companies with meaningful Current Ratio only.
ALIOF' s 10-Year Current Ratio Range
Min: 1.75  Med: 2.48 Max: 3.95
Current: 2.74
1.75
3.95
Quick Ratio 2.66
ALIOF's Quick Ratio is ranked lower than
63% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ALIOF: 2.66 )
Ranked among companies with meaningful Quick Ratio only.
ALIOF' s 10-Year Quick Ratio Range
Min: 1.7  Med: 2.40 Max: 3.8
Current: 2.66
1.7
3.8
Days Inventory 104.79
ALIOF's Days Inventory is ranked higher than
55% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. ALIOF: 104.79 )
Ranked among companies with meaningful Days Inventory only.
ALIOF' s 10-Year Days Inventory Range
Min: 88.91  Med: 102.47 Max: 123.11
Current: 104.79
88.91
123.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.98
ALIOF's Dividend Yield is ranked lower than
56% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. ALIOF: 0.98 )
Ranked among companies with meaningful Dividend Yield only.
ALIOF' s 10-Year Dividend Yield Range
Min: 0.85  Med: 1.57 Max: 2.7
Current: 0.98
0.85
2.7
Dividend Payout 0.22
ALIOF's Dividend Payout is ranked higher than
74% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 0.37 vs. ALIOF: 0.22 )
Ranked among companies with meaningful Dividend Payout only.
ALIOF' s 10-Year Dividend Payout Range
Min: 0.47  Med: 0.73 Max: 1.14
Current: 0.22
0.47
1.14
Dividend growth (3y) 14.50
ALIOF's Dividend growth (3y) is ranked higher than
72% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. ALIOF: 14.50 )
Ranked among companies with meaningful Dividend growth (3y) only.
ALIOF' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 14.5
Current: 14.5
0
14.5
Yield on cost (5-Year) 0.98
ALIOF's Yield on cost (5-Year) is ranked lower than
62% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 1.51 vs. ALIOF: 0.98 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 0.85  Med: 1.57 Max: 2.7
Current: 0.98
0.85
2.7
Share Buyback Rate 0.70
ALIOF's Share Buyback Rate is ranked higher than
93% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. ALIOF: 0.70 )
Ranked among companies with meaningful Share Buyback Rate only.
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7  Med: 0.80 Max: -81.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 39.18
ALIOF's Price/Net Cash is ranked lower than
88% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. ALIOF: 39.18 )
Ranked among companies with meaningful Price/Net Cash only.
ALIOF' s 10-Year Price/Net Cash Range
Min: 11.79  Med: 32.63 Max: 75.62
Current: 39.18
11.79
75.62
Price/Net Current Asset Value 16.37
ALIOF's Price/Net Current Asset Value is ranked lower than
75% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. ALIOF: 16.37 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALIOF' s 10-Year Price/Net Current Asset Value Range
Min: 4.58  Med: 10.95 Max: 21.66
Current: 16.37
4.58
21.66
Price/Tangible Book 11.23
ALIOF's Price/Tangible Book is ranked lower than
72% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. ALIOF: 11.23 )
Ranked among companies with meaningful Price/Tangible Book only.
ALIOF' s 10-Year Price/Tangible Book Range
Min: 2.98  Med: 4.62 Max: 10.28
Current: 11.23
2.98
10.28
Price/Projected FCF 3.29
ALIOF's Price/Projected FCF is ranked higher than
61% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. ALIOF: 3.29 )
Ranked among companies with meaningful Price/Projected FCF only.
ALIOF' s 10-Year Price/Projected FCF Range
Min: 1.84  Med: 2.68 Max: 3.18
Current: 3.29
1.84
3.18
Price/Median PS Value 2.19
ALIOF's Price/Median PS Value is ranked lower than
78% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. ALIOF: 2.19 )
Ranked among companies with meaningful Price/Median PS Value only.
ALIOF' s 10-Year Price/Median PS Value Range
Min: 0.55  Med: 0.95 Max: 4.3
Current: 2.19
0.55
4.3
Price/Graham Number 3.50
ALIOF's Price/Graham Number is ranked higher than
50% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ALIOF: 3.50 )
Ranked among companies with meaningful Price/Graham Number only.
ALIOF' s 10-Year Price/Graham Number Range
Min: 1.4  Med: 2.04 Max: 3.02
Current: 3.5
1.4
3.02
Earnings Yield (Greenblatt) (%) 4.00
ALIOF's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ALIOF: 4.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALIOF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.4  Med: 5.90 Max: 13.3
Current: 4
0.4
13.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany, 0QMN.UK,
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Actelion creates Vaxxilon together with the Max Planck Society Jun 26 2015
New data supporting gradual up-titration of ponesimod to mitigate first-dose cardiodynamic effects... Jun 25 2015
Gilead Patent for Sovaldi Rejected in China, Shares Down - Analyst Blog Jun 22 2015
Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog Jun 22 2015
Amgen Presents Interim Data on Migraine Drug AMG 334 - Analyst Blog Jun 22 2015
Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape Jun 22 2015
Blueprint Medicines (BPMC) Falls: Stock Goes Down 7.6% - Tale of the Tape Jun 22 2015
BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog Jun 19 2015
Amgen Cancer Drug Vectibix Hits Phase III Primary Endpoint - Analyst Blog Jun 19 2015
Momenta Gains on Generic Copaxone's Launch in U.S. - Analyst Blog Jun 19 2015
Qiagen, Hitachi High-Technologies Ink Molecular Testing Deal - Analyst Blog Jun 19 2015
Momenta Pharmaceuticals (MNTA) in Focus: Stock Rises 6.7% - Tale of the Tape Jun 19 2015
KYTHERA Soars on $2.1 Billion Buyout Offer from Allergan - Analyst Blog Jun 18 2015
Eli Lilly Reports Data on Migraine Drug; Inks Oncology Deals - Analyst Blog Jun 18 2015
Synergy Pharmaceuticals Soars on Constipation Drug Data - Analyst Blog Jun 18 2015
Qiagen's New Genetic Fingerprint Kits to Aid DNA Analysis - Analyst Blog Jun 18 2015
Radius Health Up on Positive Data on Fracture Candidate - Analyst Blog Jun 18 2015
Teva Announces Positive Results on Tardive Dyskinesia Drug - Analyst Blog Jun 17 2015
Genomic Health Liquid Biopsy Test Fit for Bladder Cancer - Analyst Blog Jun 17 2015
Aerie Pharmaceuticals Up on Primary Endpoint Revision - Analyst Blog Jun 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK